MAVYRET Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mavyret, and when can generic versions of Mavyret launch?
Mavyret is a drug marketed by Abbvie Inc and is included in two NDAs. There are nine patents protecting this drug.
This drug has five hundred and fourteen patent family members in forty-five countries.
The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.
DrugPatentWatch® Generic Entry Outlook for Mavyret
Mavyret was eligible for patent challenges on August 3, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 5, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for MAVYRET
International Patents: | 514 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 27 |
Drug Prices: | Drug price information for MAVYRET |
What excipients (inactive ingredients) are in MAVYRET? | MAVYRET excipients list |
DailyMed Link: | MAVYRET at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for MAVYRET
Generic Entry Dates for MAVYRET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
Generic Entry Dates for MAVYRET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
PELLETS;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MAVYRET
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Duke University | Phase 4 |
NYU Langone Health | Early Phase 1 |
Mayo Clinic | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for MAVYRET
US Patents and Regulatory Information for MAVYRET
MAVYRET is protected by nine US patents and thirteen FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MAVYRET is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting MAVYRET
Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Method for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Solid pharmaceutical compositions for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Macrocyclic proline derived HCV serine protease inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Crystal forms
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Crystal forms
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting MAVYRET
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION
Exclusivity Expiration: See Plans and Pricing
EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
Exclusivity Expiration: See Plans and Pricing
FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
Exclusivity Expiration: See Plans and Pricing
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing
NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing
TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
Exclusivity Expiration: See Plans and Pricing
TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
Exclusivity Expiration: See Plans and Pricing
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing
International Patents for MAVYRET
When does loss-of-exclusivity occur for MAVYRET?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15269306
Estimated Expiration: See Plans and Pricing
Patent: 16283018
Estimated Expiration: See Plans and Pricing
Patent: 16296709
Estimated Expiration: See Plans and Pricing
Patent: 20239679
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2017028185
Estimated Expiration: See Plans and Pricing
Patent: 2018000982
Estimated Expiration: See Plans and Pricing
Canada
Patent: 48902
Estimated Expiration: See Plans and Pricing
Patent: 90855
Estimated Expiration: See Plans and Pricing
Patent: 92722
Estimated Expiration: See Plans and Pricing
Chile
Patent: 17003350
Estimated Expiration: See Plans and Pricing
Patent: 18000138
Estimated Expiration: See Plans and Pricing
China
Patent: 6413736
Estimated Expiration: See Plans and Pricing
Patent: 7920996
Estimated Expiration: See Plans and Pricing
Patent: 8024964
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 17013305
Estimated Expiration: See Plans and Pricing
Patent: 18000391
Estimated Expiration: See Plans and Pricing
Costa Rica
Patent: 180030
Estimated Expiration: See Plans and Pricing
Patent: 180088
Estimated Expiration: See Plans and Pricing
Dominican Republic
Patent: 017000314
Estimated Expiration: See Plans and Pricing
Patent: 018000024
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 18000689
Estimated Expiration: See Plans and Pricing
Patent: 18008411
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 1890160
Estimated Expiration: See Plans and Pricing
Patent: 1890334
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 51850
Estimated Expiration: See Plans and Pricing
Patent: 13378
Estimated Expiration: See Plans and Pricing
Patent: 24941
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 50627
Estimated Expiration: See Plans and Pricing
Patent: 55203
Estimated Expiration: See Plans and Pricing
Israel
Patent: 6504
Estimated Expiration: See Plans and Pricing
Patent: 6945
Estimated Expiration: See Plans and Pricing
Japan
Patent: 17518319
Estimated Expiration: See Plans and Pricing
Patent: 18518517
Estimated Expiration: See Plans and Pricing
Patent: 18520185
Estimated Expiration: See Plans and Pricing
Patent: 21113192
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 16016127
Estimated Expiration: See Plans and Pricing
Patent: 18000218
Estimated Expiration: See Plans and Pricing
Patent: 18000746
Estimated Expiration: See Plans and Pricing
Peru
Patent: 180488
Estimated Expiration: See Plans and Pricing
Patent: 180609
Estimated Expiration: See Plans and Pricing
Philippines
Patent: 017502426
Estimated Expiration: See Plans and Pricing
Patent: 018500132
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 18102809
Estimated Expiration: See Plans and Pricing
Patent: 18105849
Estimated Expiration: See Plans and Pricing
Patent: 21102950
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 202002899V
Estimated Expiration: See Plans and Pricing
Patent: 202002900Y
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1800533
Estimated Expiration: See Plans and Pricing
Patent: 1801082
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 180021840
Estimated Expiration: See Plans and Pricing
Patent: 180025317
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering MAVYRET around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Slovenia | 2455376 | See Plans and Pricing | |
Canada | 2847910 | COMPOSES ANTIVIRAUX (ANTI-VIRAL COMPOUNDS) | See Plans and Pricing |
Canada | 2948902 | FORMES CRISTALLINES (CRYSTAL FORMS) | See Plans and Pricing |
Poland | 2579854 | See Plans and Pricing | |
Slovenia | 2368890 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MAVYRET
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2368890 | 33/2015 | Austria | See Plans and Pricing | PRODUCT NAME: OMBITASVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/982 (MITTEILUNG) 20150119 |
2692346 | CR 2017 00049 | Denmark | See Plans and Pricing | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728 |
2692346 | 51/2017 | Austria | See Plans and Pricing | PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 (MITTEILUNG) 20170728 |
2368890 | 15C0016 | France | See Plans and Pricing | PRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119 |
2368890 | 2015012 | Norway | See Plans and Pricing | PRODUCT NAME: OMBITASVIR, ELLER ET; REG. NO/DATE: EU/1/14/982 20150120 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |